logo

For the Inventor, By the Inventor

Lengnau, Switzerland

Csl Behring Lengnau Ag


USPTO Granted Patents = 13


Trademarks = 2

Forward Citations = 6

Loading Chart...
Loading Chart...

30 inventors (with patents filed for the assignee):

goldMedal Sabine Pestel (8 out of 8 patents)

silverMedal Thomas Weimer (8 out of 28 patents)

bronzeMedal Stefan Schulte (6 out of 30 patents)

4.  Steve Dower (4 out of 4 patents)

5.  Michael Wilson (3 out of 10 patents)

6.  Hans-Wilhelm Beltz (3 out of 3 patents)

7.  Matthias Pelzing (3 out of 3 patents)

8.  Hubert Metzner (3 out of 28 patents)

9.  Dallas Hartman (3 out of 3 patents)

10.  Con Panousis (2 out of 19 patents)

11.  Matthew Hardy (2 out of 9 patents)

12.  Arna Andrews (2 out of 2 patents)

13.  Kerstin Emmrich (2 out of 2 patents)

14.  Michael Moses (1 out of 3 patents)

15.  Gerhard Dickneite (1 out of 29 patents)


13 patents:

1. 12209261 - Media for the expression of recombinant vitamin K-dependent proteins (2025-01-28),
2. 11890327 - Truncated von Willebrand factor polypeptides for extravascular administration in the treatment or prophylaxis of a blood coagulation disorder (2024-02-06),
3. 11814421 - Truncated von Willebrand Factor polypeptides for treating hemophilia (2023-11-14),
4. 11564976 - Methods for preparing modified von Willebrand Factor (2023-01-31),
5. 11479578 - Protein purification and virus inactivation with alkyl glycosides (2022-10-25),
6. 11155601 - Modified von Willebrand factor having improved half-life (2021-10-26),
7. 11141466 - Modulation of FVIII immunogenicity by truncated VWF (2021-10-12),
8. 10905747 - Methods for preparing modified von Willebrand factor (2021-02-02),
9. 10808023 - Mutated von Willebrand factor (2020-10-20),
10. 10806774 - Mutated truncated von Willebrand Factor (2020-10-20),
11. 10772936 - Methods for preparing modified von Willebrand factor (2020-09-15),
12. 10688157 - Truncated von Willebrand factor polypeptides for treating hemophilia (2020-06-23),
13. 10253088 - Modified von Willebrand Factor (2019-04-09),
Company Overview
CSL Behring Lengnau AG is a prominent player in the biopharmaceutical industry, specializing in the development and manufacturing of innovative therapies derived from human plasma. The company focuses on producing high-quality biopharmaceutical products that address rare and serious medical conditions, particularly in the fields of immunology, hematology, and respiratory health. With a commitment to advancing patient care, CSL Behring Lengnau AG leverages cutting-edge technology and research to enhance treatment options globally.
Profile summary synthesized from public USPTO records and patent filings.

logo

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

13 Patents

#6 in Lengnau

#878 in Switzerland

#45,039 in the World

Lengnau, CH
Lengnau, Switzerland

Csl Behring Lengnau Ag

Forward Citations = 6

30 inventors:

goldMedal Sabine Pestel (8 out of 8 patents)

silverMedal Thomas Weimer (8 out of 28 patents)

bronzeMedal Stefan Schulte (6 out of 30 patents)

4.  Steve Dower (4 out of 4 patents)

5.  Michael Wilson (3 out of 10 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Csl Behring Lengnau Ag. Retrieved from https://idiyas.com/company/csl-behring-lengnau-ag

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…